Since the beginning of the year, China’s self-developed AI assistant DeepSeek has made a significant splash in the global AI sector, sparking a digital revolution. Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has been at the forefront of integrating AI into its core strategy. The company quickly embraced DeepSeek, launching the trial version within its group on February 9 and subsequently integrating the full-capacity DeepSeek-R1 on February 13, 2025. This move positions Sino Biopharmaceutical as one of the first domestic pharmaceutical firms to formally adopt DeepSeek-R1.
Pioneering AI Adoption in Pharma
As a pioneer in adopting DeepSeek-R1, Sino Biopharmaceutical has already mapped out its entire business scenario and is continuously exploring applications of DeepSeek across core business areas, including drug research and development, clinical medicine, production and quality management, supply chain management, and marketing. The company’s commitment to integrating AI underscores its strategic push for digital transformation, aiming to create new possibilities across various business domains.
Enhanced Capabilities with DeepSeek-R1
Compared to the trial version, DeepSeek-R1 is specifically optimized for reasoning tasks, excelling in data analysis, logical reasoning, and in-depth thinking. This advanced AI tool serves as a reliable and intelligent assistant (“BP”) for the company. By integrating a vast amount of corporate scientific research materials, DeepSeek-R1 can better understand the company’s business knowledge systems, providing more precise services for research scenarios and driving innovation in the pharmaceutical sector.-Fineline Info & Tech
Leave a Reply